ADICET BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 USD | +1.43% |
|
-13.19% | -25.13% |
Presenter SpeechUnknown Analyst (Analysts)So, good afternoon, everyone. Welcome to the 43rd De...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.4
USD
Average target price
9.6
USD
Spread / Average Target
+585.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.87% | 115M | |
| +30.84% | 49.46B | |
| +1.07% | 42.58B | |
| +49.00% | 42.49B | |
| -5.26% | 29.09B | |
| +12.58% | 26.61B | |
| -23.92% | 18.64B | |
| +7.26% | 13.16B | |
| +31.02% | 12.55B | |
| +23.79% | 12.1B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Transcript : resTORbio, Inc. Presents at 43rd annual Deutsche Bank Healthcare Conference, May-08-2018 04